Article

Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy

Department of Cardiovascular Sciences, Campus Bio-Medico University, Rome, Italy.
Journal of Cardiovascular Medicine (Impact Factor: 1.41). 11/2010; 11(11):795-800. DOI: 10.2459/JCM.0b013e32833b929c
Source: PubMed

ABSTRACT In patients with stable angina receiving percutaneous coronary intervention (PCI) prevention of periprocedural myocardial infarction by atorvastatin pretreatment was associated with reduction of endothelial activation. This mechanism was not evaluated in patients with acute coronary syndrome (ACS). The aim was to investigate effects of atorvastatin load on adhesion molecules in ACS patients undergoing PCI.
In a planned subanalysis of the ARMYDA-ACS trial, a subgroup of 44 patients were blind-tested for measurement of intercellular cell adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin plasma levels; 21 patients belonged to the atorvastatin (80 mg 12 h before PCI, with a further 40 mg preprocedure dose) and 23 to the placebo arm. Adhesion molecules were evaluated at randomization (12 h before intervention), immediately before PCI and after 8 and 24 h.
Reduction of procedural myocardial injury after statin pretreatment was confirmed in this subgroup. ICAM-1, VCAM-1 and E-selectin levels were similar at randomization and before intervention in both arms. At 8 h, ICAM-1 increase was similar in the two arms, whereas 24-h levels were lower in the atorvastatin vs. placebo group (241 ± 25 vs. 261 ± 30 ng/ml; P = 0.019). Significant attenuation of VCAM-1 elevation occurred both at 8 and 24 h in the atorvastatin group (509 ± 56 vs. 545 ± 59 ng/ml; P = 0.044 and 561 ± 58 vs. 600 ± 53 ng/ml; P = 0.025). E-selectin levels were not different at any time-point in the two arms.
In ACS patients undergoing PCI, reduction of procedural myocardial injury after atorvastatin load is associated with attenuation of endothelial inflammatory response. This may contribute to mechanisms of statin cardioprotection in this setting.

0 Followers
 · 
67 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Evidence suggests that high-dose statin pretreatment may reduce the risk of periprocedural myocardial infarction (PMI) and major adverse cardiac events (MACE) for certain patients; however, previous analyses have not considered patients with a history of statin maintenance treatment. In this meta-analysis of randomized controlled trials (RCTs), we reevaluated the efficacy of short-term high-dose statin pretreatment to prevent PMI and MACE in an expanded set of patients undergoing elective percutaneous coronary intervention. We searched the PubMed/Medline database for RCTs that compared high-dose statin pretreatment with no statin or low-dose statin pretreatment as a prevention of PMI and MACE. We evaluated the incidence of PMI and MACE, including death, spontaneous myocardial infarction, and target vessel revascularization at the longest follow-up for each study for subgroups stratified by disease classification and prior low-dose statin treatment. Twenty-four RCTs with a total of 5,526 patients were identified. High-dose statin pretreatment was associated with 59% relative reduction in PMI (odds ratio [OR]: 0.41; 95% confidence interval [CI]: 0.34-0.49; P<0.00001) and 39% relative reduction in MACE (OR: 0.61; 95% CI: 0.45-0.83; P = 0.002). The benefit of high-dose statin pretreatment on MACE was significant for statin-naive patients (OR: 0.69; 95% CI: 0.50-0.95; P = 0.02) and prior low dose statin-treated patients (OR: 0.28; 95% CI: 0.12-0.65; P = 0.003); and for patients with acute coronary syndrome (OR: 0.52; 95% CI: 0.34-0.79; P = 0.003), but not for patients with stable angina (OR: 0.71; 95% CI 0.45-1.10; P = 0.12). Long-term effects on survival were less obvious. High-dose statin pretreatment can result in a significant reduction in PMI and MACE for patients undergoing elective PCI. The positive effect of high-dose statin pretreatment on PMI and MACE is significant for statin-naïve patients and patients with prior treatment. The positive effect of high-dose statin pretreatment on MACE is significant for patients with acute coronary syndrome.
    PLoS ONE 12/2014; 9(12):e113352. DOI:10.1371/journal.pone.0113352 · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The natural history of atherosclerosis might involve coronary plaque rupture/erosion, thrombus formation and vessel lumen occlusion, clinically recognized as acute coronary syndrome (ACS). International guidelines strongly recommend early statin administration in patients admitted for ACS. In addition to lowering circulating levels of low-density lipoprotein cholesterol (LDL-c), statin treatment was shown to promote plaque stabilization or regression in several ways, including reduction of necrotic lipid core, anti-inflammatory effects and improvement of endothelial function. The aim of this review is to summarize clinical evidence on the role of statins in secondary prevention of ACS. This narrative review is based on the material found on MEDLINE and PubMed up to August 2013. We looked for the terms "statin, acute coronary syndromes" in combination with "atherosclerosis, acute myocardial infarction, pathophysiology". this review article emphasizes the relevance of the timing of statin administration to improve the outcomes after ACS. Early and continuous statin administration has emerged as key features to prevent adverse events, especially in patients admitted for ACS undergoing percutaneous coronary intervention. Clinical trials matching the improved clinical outcome with the imaging of atherosclerotic plaque stabilization/regression further supporting the effectiveness of statin therapy. However, the achievement of these goals requires high dose of statins, thus increasing the risk of adverse events. Although clinical trials and meta-analyses have provided conflicting results, it is likely that in clinical practice the rate of adverse events is higher, so that many concerns still remain about a statin high-dose approach in ACS patients. This article is protected by copyright. All rights reserved.
    European Journal of Clinical Investigation 03/2014; DOI:10.1111/eci.12255 · 2.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chez les patients à haut risque vasculaire, les statines préviennent les événements cardiovasculaires à long terme. Leur effet à court terme a été récemment évalué par des essais randomisés chez des patients bénéficiant d’une chirurgie vasculaire, d’un pontage aortocoronaire ou d’une intervention coronaire percutanée. La statine était initiée selon les cas quelques semaines à quelques heures avant l’intervention. Dans le domaine de la chirurgie vasculaire, l’étude DECREASE III a suggéré que la fluvastatine débutée avant la chirurgie diminue l’incidence des ischémies myocardiques périopératoires. Cependant, cette étude contient diverses difficultés méthodologiques, en particulier la modification du critère principal en cours d’essai. Initiées avant un pontage aortocoronaire, les statines préviendraient la fibrillation auriculaire pendant la phase hospitalière, d’après 4 essais randomisés. Ce résultat est discordant avec celui d’une méta-analyse récente d’essais publiés et non publiés, évaluant des statines au long cours, qui ne montre pas de prévention de la fibrillation auriculaire. L’administration d’une statine avant une intervention coronaire percutanée a été évalué par de nombreux essais randomisés. Dans leur grande majorité, ces essais ont trouvé un effet significatif de la statine pour prévenir la nécrose myocardique et/ou les événements cardiaques majeurs post-procédure. Cependant, la plus grande partie des événements évités étaient des nécroses purement biologiques. De plus, la définition de la nécrose n’était pas toujours conforme aux recommandations. La méta-analyse de ces essais a montré que les statines diminuent de près de moitié l’incidence des événements cardiaques majeurs post-procédure, ce qui n’est pas cohérent avec les résultats de grands essais évaluant à plus long terme une statine dans les suites d’un syndrome coronaire aigu. L’ensemble de ces essais ne paraît pas suffisant pour établir le bénéfice à court terme de la prescription d’une statine avant une intervention.
    La Presse Médicale 03/2013; 42(3):261–268. DOI:10.1016/j.lpm.2012.05.016 · 1.17 Impact Factor